Preparation And Storage
Recommended Assay Procedures
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).
Product Notices
- This antibody was developed for use in flow cytometry.
- The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
- Researchers should determine the optimal concentration of this reagent for their individual applications.
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
- BD Horizon Brilliant Violet 650 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
- Alexa Fluor® is a registered trademark of Life Technologies Corporation.
Companion Products
The B-K29 monoclonal antibody specifically binds to CD262 which is also known as, TNF-related apoptosis-inducing ligand receptor 2 (TRAIL Receptor 2, TRAIL-R2), Death receptor 5 (DR5), TRICK2, or KILLER. CD262 is a type I transmembrane protein that is encoded by TNFRSF10B (Tumor necrosis factor receptor superfamily, member 10b). CD262 forms a homotrimeric receptor complex that can bind homotrimeric TRAIL (CD253/APO-2 Ligand) and transduce apoptotic signals intracellularly through its cytoplasmic death domain (DD). CD262 is differentially expressed on cells from a wide variety of normal tissues and tumors. CD262 expression is upregulated by Interferon-α (IFN-α).
The antibody was conjugated to BD Horizon™ BV650 which is part of the BD Horizon Brilliant™ Violet family of dyes. This dye is a tandem fluorochrome of BD Horizon BV421 with an Ex Max of 405-nm and an acceptor dye with an Em Max at 650-nm. BD Horizon BV650 can be excited by the violet laser and detected in a filter used to detect APC-like dyes (eg, 660/20-nm filter). Due to the excitation and emission characteristics of the acceptor dye, there will be spillover into the APC and Alexa Fluor® 700 detectors. However, the spillover can be corrected through compensation as with any other dye combination.
Development References (6)
-
Bisgin A, Terzioglu E, Aydin C, et al. TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2010; 11(192):200. (Biology). View Reference
-
Ch'en PF, Xu XG, Liu XS, et al. Characterisation of monoclonal antibodies to the TNF and TNF receptor families. Cell Immunol. 2005; 236(1-2):78-85. (Clone-specific: Flow cytometry). View Reference
-
Chen C, Liu Y, Zheng D. An agonistic monoclonal antibody against DR5 induces ROS production, sustained JNK activation and Endo G release in Jurkat leukemia cells. Cell Res. 2009; 19(8):984-995. (Biology). View Reference
-
El-Gazzar A, Perco P, Eckelhart E et al. Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer. Mol Cancer Ther. 2010; 9(4):1007-1018. (Biology). View Reference
-
Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006; 26(19):7046-7055. (Clone-specific: Flow cytometry). View Reference
-
Vermot-Desroches C, Sergent E, Bonnin B, Wijdenes J. Characterization of monoclonal antibodies directed against trail or trail receptors. Cell Immunol. 2005; 236(1-2):86-91. (Clone-specific: Blocking, Flow cytometry, Functional assay, Inhibition). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.